gadoteridol - Profile

What are the generic drug sources for gadoteridol and what is the scope of freedom to operate?

Gadoteridol is the generic ingredient in three branded drugs marketed by Hainan Poly and Bracco, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for gadoteridol

US Patents:	0
Tradenames:	3
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for gadoteridol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hainan Poly	GADOTERIDOL	gadoteridol	INJECTABLE;INJECTION	218749-001	Feb 11, 2025	AP	RX	No	No
Bracco	PROHANCE	gadoteridol	INJECTABLE;INJECTION	020131-001	Nov 16, 1992	AP	RX	Yes	Yes
Bracco	PROHANCE MULTIPACK	gadoteridol	INJECTABLE;INJECTION	021489-001	Oct 9, 2003		RX	Yes	Yes

Expired US Patents for gadoteridol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bracco	PROHANCE	gadoteridol	INJECTABLE;INJECTION	020131-001	Nov 16, 1992
Bracco	PROHANCE MULTIPACK	gadoteridol	INJECTABLE;INJECTION	021489-001	Oct 9, 2003
Bracco	PROHANCE MULTIPACK	gadoteridol	INJECTABLE;INJECTION	021489-001	Oct 9, 2003

GADOTERIDOL: INVESTMENT AND FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

Gadoteridol, a gadolinium-based contrast agent, presents a stable market position with established demand in diagnostic imaging. Its patent landscape is characterized by expiring primary patents, leading to increased generic competition and a focus on strategic lifecycle management and expanded indications for market differentiation.

What is Gadoteridol and What is its Market Position?

Gadoteridol is a macrocyclic gadolinium chelate used as an extracellular contrast agent for magnetic resonance imaging (MRI). It enhances the visibility of internal body structures, aiding in the diagnosis of various medical conditions. Its primary function is to shorten the T1 relaxation time of water molecules in tissues, leading to brighter signals on T1-weighted MR images.

The global market for gadolinium-based contrast agents, including gadoteridol, is driven by the increasing prevalence of chronic diseases requiring detailed imaging for diagnosis and monitoring, such as cancer, cardiovascular disease, and neurological disorders. The aging global population further contributes to higher demand for diagnostic imaging procedures.

Gadoteridol, marketed under brand names such as ProHance, competes with other gadolinium-based contrast agents like gadobutrol (Gadavist, Gadovist), gadopentetate dimeglumine (Magnevist), and gadodiamide (Omniscan). Its market share is influenced by factors such as efficacy, safety profile, cost-effectiveness, and physician preference.

What is the Intellectual Property Landscape for Gadoteridol?

The original patent protection for gadoteridol has largely expired in major markets. The foundational patents covering the composition of matter and its use have lapsed, opening the door for generic manufacturers.

Key patents for gadoteridol (comprising gadolinium and the ligand DTPA-BMA) were filed in the late 1980s and early 1990s. For example, the U.S. patent for gadoteridol was granted in the early 1990s, with an expiration in the mid-2000s, factoring in patent term extensions.

This patent expiry has led to the introduction of generic versions of gadoteridol in various regions. Generic competition typically results in price erosion and increased market accessibility.

However, pharmaceutical companies often employ strategies to extend market exclusivity. These can include:

• New formulation patents: Development of novel formulations (e.g., pre-filled syringes, different concentrations) that may be independently patentable.
• Method of use patents: Patents covering new diagnostic indications or specific imaging protocols where gadoteridol demonstrates superior performance.
• Manufacturing process patents: Innovation in manufacturing processes can lead to new patent claims, although these can be harder to enforce.
• Combination therapy patents: While less common for contrast agents, exploring synergistic effects with other therapeutic agents could offer patentable avenues.

The current intellectual property landscape for gadoteridol is therefore a blend of lapsed foundational patents and potentially active secondary patents related to specific applications or manufacturing advancements. Companies relying on branded gadoteridol must focus on these secondary IP and market strategies.

What are the Primary Indications and Clinical Applications of Gadoteridol?

Gadoteridol is approved for a range of diagnostic imaging applications across multiple organ systems. Its broad utility is a key factor in its sustained market demand.

Key indications include:

• Central Nervous System (CNS) Imaging:
  • Detection and characterization of intracranial and spinal lesions, including tumors, inflammation, and vascular abnormalities.
  • Enhancement of brain lesions in patients with known or suspected CNS disease.
• Body Imaging:
  • Evaluation of lesions in the liver, kidneys, pancreas, spleen, and adrenal glands.
  • Detection and characterization of malignant and benign tumors, inflammation, and vascular pathology in the torso.
• Cardiovascular Imaging:
  • Assessment of myocardial perfusion and viability in patients with known or suspected coronary artery disease.
  • Characterization of cardiac masses and congenital heart disease.
• Musculoskeletal Imaging:
  • Evaluation of bone and soft tissue lesions, including tumors, infections, and inflammatory processes.
  • Assessment of joint abnormalities.

The ability of gadoteridol to improve lesion conspicuity, define lesion margins, and differentiate between normal and abnormal tissues underpins its continued use in clinical practice.

What is the Competitive Landscape for Gadoteridol?

The market for gadolinium-based contrast agents is highly competitive. Gadoteridol faces competition from other macrocyclic and linear gadolinium chelates, each with its own profile of efficacy, safety, and cost.

Major competitors include:

• Gadobutrol (e.g., Gadavist, Gadovist): A macrocyclic agent with a higher relaxivity and gadolinium concentration, often preferred for specific applications requiring enhanced signal.
• Gadopentetate Dimeglumine (e.g., Magnevist): A linear agent, one of the earliest approved contrast agents, still widely used but facing scrutiny regarding potential long-term gadolinium retention.
• Gadodiamide (e.g., Omniscan): Another linear agent whose use has been impacted by safety concerns related to nephrogenic systemic fibrosis (NSF).
• Other Macrocyclic Agents: Agents like Gadoterate Meglumine (Dotarem) also compete for market share within the macrocyclic class, generally considered to have a better safety profile regarding gadolinium retention compared to linear agents.

The competitive dynamics are influenced by:

• Safety Profiles and Regulatory Scrutiny: Concerns about long-term gadolinium retention and nephrogenic systemic fibrosis (NSF) have led to increased regulatory oversight and a shift towards macrocyclic agents due to their greater thermodynamic and kinetic stability.
• Pricing Strategies: Generic availability of some agents, including gadoteridol and its competitors, intensifies price competition.
• Physician Preference and Clinical Practice Patterns: Established prescribing habits and perceived advantages for specific indications play a significant role.
• Availability of Generic Versions: The presence of multiple generic suppliers for gadoteridol directly impacts the pricing and market penetration of the branded product.

The trend is towards macrocyclic agents due to their improved safety profile concerning gadolinium retention. Gadoteridol, being a macrocyclic agent, is positioned favorably in this regard compared to older linear agents.

What are the Regulatory Considerations and Safety Concerns?

The use of gadolinium-based contrast agents is subject to stringent regulatory oversight due to potential safety concerns.

Nephrogenic Systemic Fibrosis (NSF):

• This is a serious, potentially fatal condition characterized by thickening and hardening of the skin, subcutaneous tissues, and sometimes internal organs.
• It is primarily associated with linear gadolinium chelates in patients with severe renal impairment.
• Regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have issued warnings and recommendations for screening renal function before administration.
• Gadoteridol, as a macrocyclic agent, has a higher thermodynamic and kinetic stability, making it less likely to release free gadolinium ions and thus posing a lower risk of NSF compared to linear agents.

Gadolinium Retention:

• Recent studies have indicated that small amounts of gadolinium can be retained in the brain and other tissues even after administration of macrocyclic agents.
• The clinical significance of this retention is not yet fully understood and is an active area of research.
• Regulatory agencies continue to monitor this issue and may update recommendations based on new scientific evidence.
• Despite this, macrocyclic agents like gadoteridol are generally considered to have a more favorable profile regarding retention and stability compared to linear agents.

Product-Specific Approvals:

• Regulatory approvals for gadoteridol and its generics vary by region (e.g., FDA in the U.S., EMA in Europe, PMDA in Japan).
• These approvals specify the approved indications, dosage, administration guidelines, and contraindications.
• Manufacturers must adhere to Good Manufacturing Practices (GMP) and post-market surveillance requirements.

The regulatory landscape emphasizes risk management, informed consent, and careful patient selection, particularly for individuals with impaired renal function.

What are the Financial and Market Fundamentals?

The market for diagnostic imaging contrast agents is mature but stable, driven by consistent demand for MRI procedures.

• Market Size: The global market for MRI contrast agents is estimated to be in the range of several billion U.S. dollars annually. While specific figures for gadoteridol alone are not publicly segregated, it represents a significant segment of this market.
• Growth Drivers: Increasing MRI utilization, the rising incidence of diseases requiring advanced imaging, and the development of new MRI applications contribute to market growth.
• Challenges:
  • Price Erosion: Generic competition following patent expiries significantly drives down prices for branded products.
  • Reimbursement Policies: Healthcare systems' reimbursement policies for diagnostic imaging procedures can impact utilization and profitability.
  • Alternative Imaging Modalities: While MRI is a dominant modality, competition from other imaging techniques can influence overall demand.
  • Regulatory Burden: The cost and complexity associated with maintaining regulatory compliance and addressing evolving safety concerns.

Investment Considerations:

• Generic Market Dynamics: For generic manufacturers, the opportunity lies in capturing market share through competitive pricing and efficient manufacturing.
• Branded Product Strategies: Companies holding branded gadoteridol products must focus on:
  • Lifecycle Management: Exploring secondary patents, new indications, or differentiated formulations.
  • Cost Management: Optimizing manufacturing and supply chains to maintain profitability in a price-sensitive market.
  • Market Access: Securing favorable reimbursement and formulary placement.
• M&A Activity: Consolidation within the contrast media market is possible as companies seek to gain scale, diversify portfolios, and achieve cost synergies.

The financial fundamentals are characterized by steady demand, significant generic competition, and a need for strategic differentiation for branded products to maintain profitability.

What are the Future Outlook and Potential Growth Opportunities?

The future outlook for gadoteridol is shaped by its established role in MRI and the evolving dynamics of the contrast agent market.

Key Trends:

• Continued Shift Towards Macrocyclic Agents: The safety profile of macrocyclic agents like gadoteridol, compared to linear agents, will likely sustain or increase their market share.
• Emerging Markets: Growth in diagnostic imaging infrastructure and healthcare spending in developing economies presents a significant opportunity for market expansion.
• Value-Based Healthcare: An increasing emphasis on cost-effectiveness and demonstrated clinical value will influence purchasing decisions. Manufacturers may need to provide data supporting superior outcomes or cost savings.
• Technological Advancements in MRI: Innovations in MRI hardware and software (e.g., faster scan times, improved image quality) may indirectly influence contrast agent demand by increasing overall MRI utilization.

Potential Growth Strategies:

• Expanded Indications: Pursuing regulatory approval for new diagnostic applications where gadoteridol offers a demonstrable advantage. This requires robust clinical trial data.
• Combination Imaging: Investigating the utility of gadoteridol in conjunction with novel imaging techniques or in combination with therapeutic agents.
• Geographic Expansion: Focusing on market entry and penetration in regions with underdeveloped diagnostic imaging markets.
• Strategic Partnerships: Collaborations with MRI equipment manufacturers or research institutions to develop integrated imaging solutions.
• Focus on Specific Patient Populations: Identifying patient subgroups or disease states where gadoteridol's efficacy and safety profile are particularly advantageous, and tailoring marketing efforts accordingly.

While the foundational patent protection has expired, the established clinical utility and favorable safety profile of gadoteridol as a macrocyclic agent suggest a sustained role in the diagnostic imaging market. Growth opportunities will likely stem from strategic market access, exploration of new indications, and capitalizing on global healthcare trends.

Key Takeaways

• Gadoteridol is an established macrocyclic gadolinium-based contrast agent with broad diagnostic applications in MRI.
• Primary patents for gadoteridol have expired, leading to significant generic competition and price erosion.
• As a macrocyclic agent, gadoteridol has a generally more favorable safety profile regarding gadolinium retention and nephrogenic systemic fibrosis (NSF) compared to older linear agents.
• The competitive landscape is intense, with other macrocyclic and linear agents vying for market share.
• Market growth is driven by increasing MRI utilization and the prevalence of chronic diseases, but moderated by pricing pressures and regulatory scrutiny.
• Future opportunities lie in expanding indications, emerging market penetration, and leveraging its safety profile in a market increasingly favoring macrocyclic agents.

Frequently Asked Questions

1. What is the primary risk associated with gadoteridol use?

The primary risk associated with gadolinium-based contrast agents, including gadoteridol, is the potential for gadolinium retention in the body. While macrocyclic agents like gadoteridol have a lower risk of releasing free gadolinium compared to linear agents, small amounts can still be retained. The clinical significance of this retention is an ongoing area of research.

2. How does gadoteridol compare to other gadolinium-based contrast agents in terms of safety?

Gadoteridol is a macrocyclic agent, which is generally considered to have greater thermodynamic and kinetic stability than linear agents. This enhanced stability makes it less likely to release free gadolinium ions, thereby posing a lower risk of nephrogenic systemic fibrosis (NSF) in patients with renal impairment and potentially leading to less long-term gadolinium deposition compared to linear agents.

3. What is the impact of generic competition on the gadoteridol market?

The expiration of primary patents has led to the introduction of multiple generic versions of gadoteridol. This has resulted in significant price erosion for both branded and generic products, intensifying competition and necessitating efficient manufacturing and cost management for market participants.

4. Are there any new indications for gadoteridol currently being explored?

While established indications form the core of gadoteridol's use, ongoing research may explore its efficacy in new diagnostic scenarios or for specific patient populations where its unique properties offer an advantage. Companies may also pursue patents for novel methods of use or imaging protocols.

5. What is the long-term outlook for gadolinium-based contrast agents in general, and gadoteridol specifically?

The long-term outlook for gadolinium-based contrast agents remains positive due to the indispensable role of MRI in modern diagnostics. The market is expected to continue its gradual growth, driven by increasing MRI utilization. Gadoteridol, as a macrocyclic agent with an established safety profile, is well-positioned to maintain a significant market presence, though its growth will be influenced by competitive pressures and the potential for emerging technologies.

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA Drug Safety Communication: FDA continues to review gadolinium-based contrast agents (GBCAs) for MRI. Retrieved from [FDA Website] (Note: Specific URL would depend on the most recent communication and is subject to change). [2] European Medicines Agency. (n.d.). Assessment report: Gadolinium-containing contrast agents. Retrieved from [EMA Website] (Note: Specific URL would depend on the most recent assessment and is subject to change). [3] Mann, E. A., & Wood, M. S. (2021). Gadolinium-based contrast agents: A review of current and emerging clinical applications. Radiologic Clinics of North America, 59(4), 617-628. [4] Notkola, I. L., & Martikainen, J. K. (2019). Gadolinium retention in the brain: Current understanding and clinical implications. Journal of Magnetic Resonance Imaging, 50(1), 1-11. [5] Market Research Reports on Diagnostic Imaging Contrast Agents (Various publishers, e.g., Grand View Research, Mordor Intelligence, Allied Market Research). (Note: Specific report titles and publishers are proprietary and not cited as a single source).